Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside

HCV Polymerase Inhibitor Being Presented at AASLD

SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in San Francisco, California, from October 31 - November 4. ANA598 is the Company's investigational hepatitis C non- nucleoside polymerase inhibitor.

ANA598 Phase I Study Results

In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study, although definitive conclusions regarding product safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. All reported adverse events were classified as mild or moderate, with no apparent dose relationship and no pattern of events within any body system. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 with a half-life of 24 to 30 hours in the fasted state and 22 hours in the fed state, consistent with the potential for once-daily or twice-daily oral dosing. In the cohort that received two 800 mg
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015  New product launches are critical ... role in educating thought leaders about new products, Medical ... influence how well a new therapy performs at launch. ... research and consulting leader Best Practices, LLC, critical aspects ... focus on are early stage thought leader (TL) interaction, ...
(Date:7/2/2015)... , July 2, 2015 Roche,s ... conspicuously high-growth market segment in hematology testing, according ... said that Roche,s recent unveiling of its Bloodhound digital ... cobas m 511 hematology analyzer – ... capture growth enjoyed by current leader CellaVision, but ...
(Date:7/2/2015)... LAKEWAY, Texas , July 2, 2015   ... on being the leading provider for non-invasive aesthetics in ... offer state-of-the-art tattoo removal treatments with the Astanza Duality ... transform their well being through various medical and laser ... patients with unwanted ink a clear solution to their ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 7Diabetics Twice as Likely to Have Hearing Loss; Missouri HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; Missouri HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; Missouri HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4
(Date:7/2/2015)... ... 02, 2015 , ... Following the recent report by JAMA Internal Medicine ... merely overweight Americans, Samir Becic emphatically declared a war on obesity in the United ... Becic said. "We must understand the magnitude of this discovery. For that reason, I ...
(Date:7/2/2015)... ... , ... With summer in full swing, Americans are flocking to Canada’s many lakes to reel ... fishing in the world, and it’s easy to understand why. From the Pacific Northwest Coast ... , Recreational fishing is a huge industry, and Americans make up the vast majority of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Get ... the SIGVARIS PERFORMANCE SOCKS. Since the socks were first introduced, they have rapidly ... significant popularity has inspired four new, fun shades including: blue, lime, pink and ...
(Date:7/2/2015)... San Diego, CA (PRWEB) , ... July 02, 2015 , ... ... lifestyle and a passion for social fitness. Built to function as a lifestyle community, ... while giving them the opportunity to network, meet, and participate in discussions or group ...
(Date:7/2/2015)... Pennsylvania (PRWEB) , ... July ... ... largest e-commerce janitorial supply company , announced today that it has ... Products. The acquisition will make CleanItSupply.com the largest distributor of Rubbermaid Commercial ...
Breaking Medicine News(10 mins):Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:CleanItSupply.com Acquires eRubbermaid.com 2
... suntan is mostly associated with good health and vitality. However, ... body to manufacture vitamin D. //It doesn't take much sunlight ... certainly far less than it takes to get a suntan. ... complex motivations involved with UV light (UVL) tanning behavior. For ...
... Romond reported from two separate trials that Breast ... Herceptin therapy using trastuzumab. //The results of their ... England Journal of Medicine. The researchers compiled results ... only chemotherapy with patients receiving both chemotherapy and ...
... from Kyoto University have found that daily gargling with povidione-iodine ... the study have been published in the American Journal of ... healthy volunteers between the age group of 18 to 65. ... the first group gargled water with povidone-iodine, the second group ...
... There is an insufficient supply of deceased donor kidneys ... of living donor kidney transplants.// ,A recent ... focuses on the insufficient supply of transplantable kidneys, strategies ... living donor renal transplants, and the results of the ...
... loss of sexual interest have often been associated with ... men who are long-term alcohol users,// with the prevalence ... cause gonadal disorders, including structural testicular changes and a ... might be involved in the hypogonadism and feminization phenotype. ...
... of insults, such as surgery, infection and injury by ... of the immune system, creating a number of potent ... for fighting infection, may damage the host. Its strength ... mediators being the key mediators. ,Recently, Robert ...
Cached Medicine News:Health News:Trastuzumab therapy effective for Breast cancer patients with Her-2/neu positive 2Health News:Daily Gargling May Prevent Common Colds 2Health News:Strategies To Boost Living Donor Kidney Transplants 2Health News:Detrimental Effect Of Chronic Alcoholism On Male Fertility 2Health News:The ideal composition of intravenous lipid emulsion 2
... With the OPMI VISU 210, Carl Zeiss ... be described as absolute state-of-the-art for ophthalmic surgery. ... placed on it by surgeons and it offers ... and contrast. With its completely integrated assistant's microscope ...
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
MONOJECT Brown Stopper...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: